AC01
Asset
Activates the ghrelin receptor to enhance cardiac contractility.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 2
- Trials
- 1
- Developer
Trial NCT07584967 is still running. Trial NCT07584967 started on Nov 15, 2026. clinicaltrials.gov
Indications
1Heart failure with reduced ejection fraction
Phase 2, Recruiting, NCT07584967, clinicaltrials.gov, Nov 12, 2026
In the full profile
- Owner and partners1
- Trials2
- Competitors8
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.